David A. Siegel Cassava Sciences Inc Transaction History
Two Sigma Advisers, LP
- $42.8 Billion
- Q1 2025
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Cassava Sciences Inc stock. As of the latest transaction made, Two Sigma Advisers, LP holds 908,600 shares of SAVA stock, worth $2.13 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
908,600
Previous 606,700
49.76%
Holding current value
$2.13 Million
Previous $1.43 Million
4.82%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding SAVA
# of Institutions
147Shares Held
15.6MCall Options Held
1.67MPut Options Held
1.26M-
Black Rock Inc. New York, NY3.22MShares$7.53 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.44MShares$5.71 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA1.03MShares$2.4 Million0.0% of portfolio
-
State Street Corp Boston, MA874KShares$2.05 Million0.0% of portfolio
-
Jpmorgan Chase & CO New York, NY790KShares$1.85 Million0.0% of portfolio
About CASSAVA SCIENCES INC
- Ticker SAVA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 40,097,900
- Market Cap $93.8M
- Description
- Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...